No Data
Sichuan Hebang Biotechnology (603077.SH): Glyphosate production line running at full capacity in the fourth quarter.
Gelonghui reported on January 3 that Sichuan Hebang Biotechnology (603077.SH) stated on the investor interaction platform that the company's Glyphosate production line is running at full capacity in the fourth quarter, and the financial situation related to gross margin should refer to the company's regular reports disclosed later.
Individual Investors Among Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Largest Stockholders and Were Hit After Last Week's 3.9% Price Drop
Sichuan Hebang Biotechnology (603077.SH): First buyback of 1.5039 million shares.
On December 16, Gelonghui reported that Sichuan Hebang Biotechnology (603077.SH) announced the first repurchase under its current repurchase plan through centralized bidding on December 16, 2024, totaling 1,503,900 shares, accounting for 0.02% of the company's total equity. The highest price paid was 2.30 yuan/share, the lowest price was 2.29 yuan/share, and the total amount paid was 3,449,476.26 yuan.
Sichuan Hebang Biotechnology's (SHSE:603077) Five-year Earnings Growth Trails the 9.1% YoY Shareholder Returns
Sichuan Hebang Biotechnology (603077.SH): The second phase of employee stock ownership plan stock sale is completed.
Gelonghui on November 20 reported that sichuan hebang biotechnology (603077.SH) announced that as of the date of this announcement, all company stocks held by the second employee stock ownership plan have been sold through centralized bidding trading, and the implementation of this employee stock ownership plan has been completed and terminated. Subsequently, the company will carry out asset liquidation and distribution work in accordance with the relevant regulations of this employee stock ownership plan.
Sichuan Hebang Biotechnology (603077.SH): The company's project in Indonesia has recently commenced.
Golden Union News on November 15th: Sichuan Hebang Biotechnology (603077.SH) stated on the investor interaction platform that 1. The company's Indonesia project has recently started. 2. Since 2024, the caustic soda market has been under pressure due to increased capacity and declining downstream demand, leading to continuous price declines and exceptionally fierce market competition. As one of the only three caustic soda production and sales companies in the southwest region, the company has invested in Chongqing Heyou, optimizing the downstream customers and channels, improving the competitive environment of the caustic soda business, and helping stabilize sales prices in the caustic soda market, avoiding unnecessary vicious competition, which is beneficial to both parties. 3. Your suggestion.
Sichuan Hebang Biotechnology (SHSE:603077) Has Some Way To Go To Become A Multi-Bagger
